LONDON - Oncolytic virus startup Theolytics Ltd. is looking to raise a series A round as it prepares to take its first product into phase I in the treatment of multiple myeloma.

PERTH, Australia – Australian immuno-oncology company Imugene Ltd. signed a deal to in-license an oncolytic virus known as CF33 from the City of Hope Comprehensive Cancer Center in Los Angeles, in a move to bolster its pipeline and open up a new area of growth for the company, said CEO Leslie Chong.